These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 21229626)
1. Clinical and biological characteristics of breast cancer. Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A J BUON; 2010; 15(4):660-7. PubMed ID: 21229626 [TBL] [Abstract][Full Text] [Related]
2. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer]. Wang YJ; Wang N; Wang B; Qin WX; Xue CY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082 [TBL] [Abstract][Full Text] [Related]
4. Predicting axillary sentinel node status in patients with primary breast cancer. Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005 [TBL] [Abstract][Full Text] [Related]
5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124 [TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancers: unique clinical presentations and outcomes. Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062 [TBL] [Abstract][Full Text] [Related]
7. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040 [TBL] [Abstract][Full Text] [Related]
8. Role of E-cadherins in development of lymphatic tumor emboli. Gupta A; Deshpande CG; Badve S Cancer; 2003 May; 97(9):2341-7. PubMed ID: 12712492 [TBL] [Abstract][Full Text] [Related]
9. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I J BUON; 2012; 17(2):277-83. PubMed ID: 22740206 [TBL] [Abstract][Full Text] [Related]
10. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482 [TBL] [Abstract][Full Text] [Related]
11. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304 [TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma]. Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937 [TBL] [Abstract][Full Text] [Related]
13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512 [TBL] [Abstract][Full Text] [Related]
15. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704 [TBL] [Abstract][Full Text] [Related]
16. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015 [TBL] [Abstract][Full Text] [Related]
17. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases. Gwin K; Wheeler DT; Bossuyt V; Tavassoli FA Int J Surg Pathol; 2010 Feb; 18(1):27-35. PubMed ID: 19282292 [TBL] [Abstract][Full Text] [Related]
18. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Tong LC; Nelson N; Tsourigiannis J; Mulligan AM Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301 [TBL] [Abstract][Full Text] [Related]
19. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613 [TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer]. Zhang P; Xu BH; Ma F; Li Q Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]